Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue (note 9) | — | — | — | $7,500 |
| Operating expenses: | ||||
| Research and development | 99,224 | 74,985 | 187,732 | 136,185 |
| General and administrative | 23,931 | 19,244 | 47,751 | 38,282 |
| Total operating expenses | 123,155 | 94,229 | 235,483 | 174,467 |
| Loss from operations | (123,155) | (94,229) | (235,483) | (166,967) |
| Other income: | ||||
| Interest income | 12,145 | 7,199 | 19,052 | 15,282 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's G&A?
- Xenon Pharmaceuticals (XENE) reported G&A of $23.93M in Q2 2026.
- How has Xenon Pharmaceuticals's G&A changed year-over-year?
- Xenon Pharmaceuticals's G&A increased by 24.4% year-over-year, from $19.24M to $23.93M.
- What is the long-term trend for Xenon Pharmaceuticals's G&A?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's G&A has grown at a 38.0% compound annual growth rate (CAGR), from $21.97M to $79.63M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Xenon Pharmaceuticals's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude